Unmet needs in the treatment of schizophrenia: New targets to help different symptom domains

Journal of Clinical Psychiatry

Volumn 75, Issue SUPPL. 1, 2014, Pages 21-26

  Citrome, Leslie ^a,b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b Medical Park Drive ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; AMPA RECEPTOR; BITOPERTIN; CLOZAPINE; CYCLOSERINE; DEXTRO SERINE; DOPAMINE; ENCENICLINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GLYCINE; GLYCINE TRANSPORTER 1; IONOTROPIC RECEPTOR; KAINIC ACID RECEPTOR; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; SARCOSINE; BUNGAROTOXIN RECEPTOR; SERINE;

ARTICLE; COGNITION; DOPAMINERGIC SYSTEM; DRUG SAFETY; HUMAN; INTERNEURON; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; SCHIZOPHRENIA; STRATEGIC PLANNING; SYMPTOM; TREATMENT PLANNING; COGNITIVE DEFECT; DRUG ANTAGONISM; DRUG POTENTIATION; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; REVIEW;

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; GLYCINE; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, GLUTAMATE; SCHIZOPHRENIA; SERINE;

EID: 84898680726     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13049su1c.04     Document Type: Article

References (32)

1. Leucht S, Corves C, Arbter D, et al. Second-generation versus firstgeneration antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41. doi:10.1016/S0140-6736(08)61764-X PubMed
2. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-tohead comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152-163. doi:10.176/api.ajp.208. 08030368 PubMed
3. Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs. 2013;27(11):879-911. doi:10.107/s40263-013-0105-7 PubMed
4. Correll CU, Gallego JA. Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice. Psychiatr Clin North Am. 2012;35(3):661-681. doi:10.1016/j.psc.2012.06.07 PubMed
5. Citrome L. Treatment-resistant schizophrenia: what can we do about it? Curr Psychiatry. 2011;10(6):52-59.
6. Singh SP, Singh V, Kar N, et al. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry. 2010;197(3):174-179. doi:10.192/bjp.bp.109.06710 PubMed
7. Buchanan RW, Kreyenbuhl J, Kelly DL, et al, for the Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71-93. doi:10.1093/schbul/sbp16 PubMed
8. Kantrowitz JT, Javitt DC. Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. Clin Schizophr Relat Psychoses. 2010;4(3):189-200. doi:10.371/CSRP.4.3.6 PubMed
9. Tsapakis EM, Travis MJ. Glutamate and psychiatric disorders. Adv Psychiatr Treat. 2002;8(3):189-197. doi:10.192/apt.8.3.189
10. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron. 2003;40(5):881-884. doi:10.1016/S0896-6273(03)0757-8 PubMed
11. Stahl SM. Novel therapeutics for schizophrenia: targeting glycine modulation of NMDA glutamate receptors. CNS Spectr. 2007;12(6):423-427. PubMed
12. Stone JM. Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia? Ther Adv Psychopharmacol. 2011;1(1):5-18. doi:10.17/ 2045125314079 PubMed
13. Kantrowitz JT, Javitt DC. Glutamate: new hope for schizophrenia treatment. Curr Psychiatry. 2011;10(4):69-74.
14. Citrome L. Neurochemical models of schizophrenia: transcending dopamine. Curr Psychiatry. 2011;10(9):S10-S14.
15. Stahl MS. Stahl?s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd ed. New York, NY: Cambridge University Press; 2008.
16. Kantrowitz JT, Javitt DC. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull. 2010;83(3-4):108-121. doi:10.1016/j.brainresbul. 2010.04.06 PubMed
17. Schoepp DD. New directions in the treatment of schizophrenia: modulators of mGlu2 and/or mGlu3 receptors. Neuropsychopharmacology. 2006;31 (suppl 1):S25-S26.
18. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007;13(9):1102-1107. doi:10.1038/nm1632 PubMed
19. Kinon BJ, Zhang L, Millen BA, et al, for the HBBI Study Group. A multicenter, inpatient, phase 2, double-blind, placebo-controlled doseranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol. 2011;31(3):349-355. doi:10.1097/JCP.0b013e318218dcd5 PubMed
20. Lilly stops phase III development of pomaglumetad methionil for thetreatment of schizophrenia based on efficacy results. Indianapolis, IN: Eli Lilly and Company; August 29, 2012. https://investor.lilly.com/releasedetail. cfm?ReleaseID=703018. Accessed January 31, 2014.
21. Goff DC, Lamberti JS, Leon AC, et al. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology. 2008;33(3):465-472. doi:10.1038/sj.np.13014 PubMed
22. Muscatello MR, Bruno A, Pandolfo G, et al. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. J Psychopharmacol. 2011;25(5):667-674. doi:10.17/0269810372548 PubMed
23. Hashimoto K. Glycine transport inhibitors for the treatment of schizophrenia. Open Med Chem J. 2010;4:10-19. PubMed
24. Tsai GE, Lin PY. Strategies to enhance N-methyl-d-aspartate receptormediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des. 2010;16(5):522-537. doi:10.2174/ 138161210790361452 PubMed
25. Lane HY, Liu YC, Huang CL, et al. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry. 2008;63(1):9-12. doi:10.1016/j.biopsych.207.04.038 PubMed
26. Javitt DC, Duncan L, Balla A, et al. Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol Psychiatry. 2005;10(3):275-287. doi:10.1038/sj.mp.40152 PubMed
27. Umbricht D, Martin-Facklam M, Pizzagalli F, et al. Glycine transporter type 1 (GlyT1) inhibitor RG1678: results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. In: International Congress on Schizophrenia Research (ICOSR) 13th Meeting Abstracts. Schizophr Bull. 2011;37(suppl 1):324. PubMed
28. Roche provides update on the first two of six phase III studies of bitopertin in schizophrenia. Basel, Switzerland: Roche; January 21, 2014. http://www.roche.com/media/mediareleases/med-cor-2014-01-21.htm. Accessed January 31, 2014
29. Umbricht D, Yoo K, Youssef E, et al. Glycine transporter type 1 (GlyT1) inhibitor RG1678: positive results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. In: American College of Neuropsychopharmacology 49th Annual Conference Abstracts. Neuropsychopharmacology. 2010;35(suppl 1):S320-S321.
30. Roche late-stage pipeline update. London, England: Roche; December 9, 2010. www.roche.com/irp101209.pdf. Accessed January 31, 2014.
31. Hofmann C, Banken L, Hahn M, et al. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers. Clin Ther. 2012;34(10):2061-2071. doi:10.1016/j. clinthera.2012.08.010 PubMed
32. Meltzer HY, Gawryl M, Ward S, et al. EVP-6124, an alpha-7 nicotinic partial agonist, produces positive effects on cognition, clinical function, and negative symptoms in patients with chronic schizophrenia on stable antipsychotic therapy. In: American College of Neuropsychopharmacology 50th Annual Meeting Abstracts. Neuropsychopharmacology. 2011;36(suppl 1):S170-S171.